{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:03:58Z","timestamp":1780650238667,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xkme.2026.101350","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:30:02Z","timestamp":1775100602000},"page":"101350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roxadustat in the Treatment of Pure Red Cell Aplasia Associated With Anti-EPO Antibodies"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1482-3640","authenticated-orcid":false,"given":"Blanca","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentino","family":"Villanego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Rodr\u00edguez Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Paz Garrastazul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auxiliadora","family":"Mazuecos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2026.101350_bib1","article-title":"Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis","volume":"2016","author":"Cody","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.xkme.2026.101350_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2215\/CJN.02440607","article-title":"Pure red cell aplasia induced by erythropoiesis-stimulating agents","volume":"3","author":"Pollock","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101350_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211005984","article-title":"Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review","volume":"49","author":"Cai","year":"2021","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.xkme.2026.101350_bib4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/0886022X.2020.1803087","article-title":"Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"42","author":"Zhang","year":"2020","journal-title":"Ren Fail"},{"issue":"2","key":"10.1016\/j.xkme.2026.101350_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/ijn.IJN_129_19","article-title":"Acquired pure red cell aplasia following recombinant erythropoietin (darbepoetin-alfa) therapy","volume":"30","author":"Padhi","year":"2020","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.xkme.2026.101350_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174583","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages","volume":"912","author":"Mima","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101350_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.21873\/invivo.12892","article-title":"Treatment of renal anemia in patients with hemodialysis using hypoxia-inducible factor (HIF) stabilizer, roxadustat: a short-term clinical study","volume":"36","author":"Mima","year":"2022","journal-title":"In Vivo"},{"issue":"3","key":"10.1016\/j.xkme.2026.101350_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1751-553X.2009.01186.x","article-title":"Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis","volume":"32","author":"El-Din","year":"2010","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101350_bib10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1523-1755.2005.00514.x","article-title":"Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients","volume":"68","author":"Kharagjitsingh","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2026.101350_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/ijn.IJN_229_20","article-title":"Acquired pure red cell aplasia and recombinant erythropoietin","volume":"31","author":"Padhi","year":"2021","journal-title":"Indian J Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101350_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/2175-8239-jbn-2018-0054","article-title":"Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review","volume":"41","author":"Lacreta","year":"2019","journal-title":"J Bras Nefrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101350_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/sdi.12991","article-title":"Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease","volume":"34","author":"Wu","year":"2021","journal-title":"Semin Dial"},{"issue":"10","key":"10.1016\/j.xkme.2026.101350_bib14","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood-2005-02-0508","article-title":"Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the research on adverse drug events and reports (RADAR) project","volume":"106","author":"Bennett","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xkme.2026.101350_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s13730-024-00865-3","article-title":"Positive response of a hemodialysis patient with pure red cell aplasia on recombinant human erythropoietin therapy to cyclosporine and Roxadustat","volume":"13","author":"Ma","year":"2024","journal-title":"CEN Case Rep"},{"issue":"2","key":"10.1016\/j.xkme.2026.101350_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000513423","article-title":"Roxadustat improves erythropoietin antibody-mediated pure red cell aplasia in a patient with hemodialysis","volume":"51","author":"Li","year":"2022","journal-title":"Blood Purif"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:15:06Z","timestamp":1780647306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526001111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2590059526001111"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101350","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roxadustat in the Treatment of Pure Red Cell Aplasia Associated With Anti-EPO Antibodies","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101350"}}